Literature DB >> 7589828

Albuminuria and poor glycemic control predict mortality in NIDDM.

M A Gall1, K Borch-Johnsen, P Hougaard, F S Nielsen, H H Parving.   

Abstract

The impact of microalbuminuria and macroalbuminuria on mortality was evaluated prospectively in 328 Caucasian patients with non-insulin-dependent diabetes mellitus (NIDDM) followed for 5 years. One hundred ninety-one (109 men and 82 women) patients with normoalbuminuria (albumin excretion rate [AER] < 30 mg/24 h), 86 (50 men and 36 women) patients with microalbuminuria (AER 30-299 mg/24 h), and 51 (43 men and 8 women) patients with macroalbuminuria (AER > or = 300 mg/24 h) < 66 years old at entry were followed from 1987 until death or until 1 January 1993. Mean age at entry was 54 (SD 9) years. In January 1993, 8% of patients with normoalbuminuria, 20% of patients with microalbuminuria, and 35% of patients with macroalbuminuria had died (predominantly from cardiovascular disease) (P < 0.01 [normoalbuminuria versus micro- and macroalbuminuria] and P < 0.05 [microalbuminuria versus macroalbuminuria]). Cox multiple regression analysis revealed significant predictors of all-cause mortality to be preexisting coronary heart disease (relative risk [95% confidence interval]), 2.9 (1.6-5.1); log10AER (factor 10), 1.9 (1.4-2.6); HbA1c level (%), 1.2 (1.0-1.4); and age (years), 1.08 (1.03-1.13). Significant predictors of cardiovascular mortality included preexisting coronary heart disease, 6.1 (2.8-13.5); macroalbuminuria, 2.5 (1.1-5.8); HbA1c level (%), 1.3 (1.1-1.6); and systolic blood pressure (10 mmHg), 1.2 (1.0-1.4). Univariate Cox survival analysis in the normoalbuminuric group revealed that AER above the median of 8 mg/24 h was associated with an increased all-cause mortality risk of 2.7 (0.93-7.69) (P = 0.07).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589828     DOI: 10.2337/diab.44.11.1303

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  52 in total

Review 1.  Complications of diabetes: renal disease and promotion of self-management.

Authors:  A Melville; R Richardson; D Lister-Sharp; A McIntosh
Journal:  Qual Health Care       Date:  2000-12

Review 2.  Antiproteinuric effect of RAS blockade: new mechanisms.

Authors:  Markus Lassila; Mark E Cooper; Karin Jandeleit-Dahm
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

3.  Short-term impact of HbA1c on morbidity and all-cause mortality in people with type 2 diabetes: a Danish population-based observational study.

Authors:  M V Skriver; H Støvring; J K Kristensen; M Charles; A Sandbæk
Journal:  Diabetologia       Date:  2012-06-27       Impact factor: 10.122

4.  Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-12-09       Impact factor: 10.122

Review 5.  Treatment of hypertension in diabetic patients with nephropathy.

Authors:  R Komers; S Anderson
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 6.  Clinical significance of glycated hemoglobin in the acute phase of ST elevation myocardial infarction.

Authors:  Chiara Lazzeri; Serafina Valente; Marco Chiostri; Maria Grazia D'Alfonso; Gian Franco Gensini
Journal:  World J Cardiol       Date:  2014-04-26

Review 7.  Drug treatment of hypertension complicating diabetes mellitus.

Authors:  M J MacLeod; J McLay
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

8.  Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study.

Authors:  P Rossing; P Hougaard; K Borch-Johnsen; H H Parving
Journal:  BMJ       Date:  1996-09-28

9.  The enormity of chronic kidney disease in Nigeria: the situation in a teaching hospital in South-East Nigeria.

Authors:  Ifeoma I Ulasi; Chinwuba K Ijoma
Journal:  J Trop Med       Date:  2010-06-02

10.  Correlation between changes of blood pressure with insulin resistance in type 2 diabetes mellitus with 4 weeks of pioglitazone therapy.

Authors:  L M Hettihewa; S S Jayasinghe; K G Imendra; T P Weerarathna
Journal:  Int J Diabetes Dev Ctries       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.